アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Product was previously marketed under the MitoSciences sub-brand.
The cells were treated for 24 hours with a 0.5mM solution of Deferoxamine (DFO). DFO is used as a hypoxia-mimetic agent to stabilize Hypoxia Inducible Factor 1 (HIF-1). DFO stabilizes HIF-1 through the inhibition of Prolyl Hydroxylases (PHDs) which target HIF-1 through degradation. The mechanism of DFO inhibition is likely through the chelation of Fe2+ bound to the active site of PHD which is required for enzymatic activity.
Our Abpromise guarantee covers the use of ab116322 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration.|
ab116322 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"